Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Joseph Kelley
AddedFeb 15, 2024
UpdatedMay 1, 2026
Joseph Kelley

Joseph Kelley

Board Member, Xylyx Bio

Joseph Kelley's Career

Xylyx Bio
Xylyx Bio

New York, US

Board Member· Board
Aztherapies
Aztherapies

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Joseph Kelley's Career

Xylyx Bio
Xylyx Bio
Seed$2.4M172016New York, US
Board Member· Board

Leadership at Xylyx Bio

Sue HalliganSue HalliganFounder
Andrea NyeAndrea NyeCEO

Similar to Xylyx Bio

Sylvatica BiotechSylvatica BiotechNorth Charleston, SC, USDevelopment, ResearchSylvatica BiotechNorth Charleston, SC, US

Sylvatica Biotech, Inc.: Pioneering commercial physical and biological research since 2015.

Seed · $12.6M7
XilisXilisDurham, NC, USDrug Discovery, Precision Healthest. 2019XilisDurham, NC, US · est. 2019

Next-gen precision health tech provider for advanced medicine and drug discovery.

Series A · $92M92
LyGenesisLyGenesisPittsburgh, PA, USBiotech, Cell Therapyest. 2017LyGenesisPittsburgh, PA, US · est. 2017

LyGenesis: A biotech firm pioneering in lymph node-based organ regeneration, primarily targeting liver diseases.

Series A · $45.7M6
BioXyTranBioXyTranNewton, MA, USDrugs, Therapeuticsest. 2008BioXyTranNewton, MA, US · est. 2008

BioXyTran, Inc.: A US biopharmaceutical firm developing anti-necrosis drugs for ischemia and stroke.

Public · $1.2M30
Aztherapies
Aztherapies
Series B$99.8M382011Boston, MA, US
Board Member· Board

Leadership at Aztherapies

George AlexGeorge AlexCEO
David R. ElmalehDavid R. ElmalehBoard Member
Rudolph TanziRudolph TanziBoard Member
Marc De GaridelMarc De GaridelBoard Member
Dr George D BehrakisDr George D BehrakisBoard Member

Similar to Aztherapies

NeuroTherapiaNeuroTherapiaOhio, IL, USTherapeuticsest. 2015NeuroTherapiaOhio, IL, US · est. 2015

NeuroTherpia, Inc.: Innovating therapies for neuroinflammatory diseases since 2015.

Series A · $11.5M4
Inflammasome TherapeuticsInflammasome TherapeuticsNewton, MA, USDisease Therapiesest. 2019Inflammasome TherapeuticsNewton, MA, US · est. 2019

Developing innovative therapies for prevalent degenerative diseases at Inflammasome Therapeutics Inc.

Series A · $3.8M10
Lysosomal TherapeuticsLysosomal TherapeuticsCambridge, MA, USDrug Developmentest. 2011Lysosomal TherapeuticsCambridge, MA, US · est. 2011

US-based Lysosomal Therapeutics Inc innovates in neurodegeneration research, developing treatments for severe neurological diseases.

Series A · $24.8M5
Endlyz TherapeuticsEndlyz TherapeuticsBoston, MA, USTherapeuticsest. 2021Endlyz TherapeuticsBoston, MA, US · est. 2021

Boston-based medical organization developing therapeutics for neurodegenerative diseases.

Angel · $3.3M50

Joseph Kelley's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Joseph Kelley

Venita McCellonVenita McCellonBoard Member · AZZJulieann Esper RainvilleJulieann Esper RainvilleBoard Member · Azalea Health InnovationsDaniel R FeehanDaniel R FeehanBoard Member · AZZTyler IgnatowskiTyler IgnatowskiBoard Member · MultipleBill GreeneBill GreeneBoard Member · Arizona Financial Credit Union